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Aromatase cytochrome P450 gene expression in endometrial carcinoma
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Summary We analysed aromatase gene expression and its regulation in seven cases of endometrioid
endometrial carcinoma. Immunohistochemistry revealed the presence of strong aromatase immunoreactivity in
the stromal cells ofcarcinoma in five out of seven cases. A polymerase chain reaction after reverse transcription
(RT-PCR) revealed varying levels of aromatase transcripts (0.1-27.0 amol ng'- total mRNA) in five cases.
The alternative use of multiple exons 1 was also examined by identifying various human aromatase transcripts
specific for exons 1 in RT-PCR products. Gonadal type or exon ld was primarily used in three cases in which
aromatase overexpression was not detected. The two cases in which fibroblasts type or exon lb was used with
other exons 1 as minor transcripts demonstrated aromatase overexpression in immunohistochemistry and RT-
PCR analysis. Further studies are required, but alternative splicing as well as use ofmultiple exons 1 transcripts
may result in increased aromatase expression in stromal cells observed in endometrial carcinoma.
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Local oestrogen production, i.e. the conversion of C19 steroids
to oestrogens catalysed by aromatase cytochrome P450, has
been considered to play important roles in the progression of
human oestrogen-dependent neoplasms (Sasano et al., 1994;
Bulun et al., 1994). Wepreviously demonstrated the presence of
possible in situ production of oestrogens in the stromal cells of
endometrial carcinoma by immunohistochemistry, in situ
hybridisation and biochemical methods (Watanabe et al.,
1995). Simpson et al. have demonstrated that the human
aromatase gene contains a number oftissue-specific promoters
that direct aromatase expression in human placenta as well as
in human ovarian and adipose stromal cells (Means et al., 1989,
1991; Mahendroo et al., 1991). In addition, tissue-specific
expression of the human aromatase gene by alternative
ulitisation of multiple exons 1 as novel promoters has been
recently demonstrated to contribute to overexpression of
aromatase in situ in various human sex steroid-dependent
neoplasms (Harada etal., 1993; Bulun etal., 1994a, b). Bulun et
al. (1994c), in particular, studied aromatase gene expression in
eight cases of endometrial carcinoma and detected varying
levels ofP450arom transcripts in all eights cases. However, they
examined alternative promoter use in only two cases and did
not study the correlation of the promoters used and
overexpression of aromatase genes. Therefore, in this study,
we examined exons 1 of the human aromatase gene in seven
cases of endometrioid endometrial carcinoma using the
products of reverse transcription-polymerase chain reaction
(RT-PCR) analysis to examine whether such an alternative
splicing is present in this neoplasm. We also examined whether
the use of any specific exons 1 may be correlated with
aromatase expression in the specimens, which was determined
by quantitation of aromatase mRNA in RT-PCR products
and immunohistochemistry, in order to characterise further the
in situ oestrogen metabolism of human endometrial malig-
nancies.
Materials and methods
Endometrial carcinoma
Seven endometrioid endometrial carcinoma specimens were
collected at Tohoku University Hospital, Sendai, Japan, in
1994. The clinical and pathological findings are summarised in
Table I. This histopathological classification was based on the
World Health Organization Typing of Uterine Tumors
(Silverberg and Kurman, 1992). These specimens were
immediately frozen and stored at - 80°C until use. Specimens
for immunohistochemical study were fixed in 4% paraformal-
dehyde (pH 7.4) for 18 h at 4°C and embedded in paraffin.
Immunohistochemistry
Immunohistochemical procedures employed in this study
were described previously by Watanabe et al. (1995).
Immunostaining was carried out by the biotin-streptavidin
amplified method using the Histofine immunostaining system
(Nichirei, Tokyo, Japan).
The primary antibody used in this study was rabbit IgG
anti-aromatase antibody prepared against enyzme purified
from human placenta (Harada et al., 1988). Preparation of
the antibody and immunoblotting and immunohistochemical
techniques using this antibody have been described elsewhere
(Sasano et al., 1994; Harada, 1988). Control sections were
incubated with normal rabbit serum or 0.01 M phosphate-
buffered saline solution (PBS). No immunoreactivity was
observed in these control sections. The aromatase labelling
index, or the number of stromal cells in which relatively
strong aromatase immunoreactivity was observed, was
defined as follows: (-) 0-5%; (+) 5-25% and (+ +)
>25% positive cells among the stromal cells in the
carcinoma, as previously described by Watanabe et al. (1995).
Quantitative analysis of aromatase mRNA by RT-PCR
The methods have been previously described by Harada et
al. (1992a,b, 1996). Briefly, samples were homogenised in five
volumes of 5 M guanidine thiocyanate containing 5 mM
sodium citrate and 0.5% sodium sarcosyl. The total RNA
fraction from all homogenates was prepared as described by
Chingwin et al. (1979). The measurement of aromatase
mRNA in these samples was performed by RT-PCR using a
specific sense primer labelled with a fluorescent dye and a
specific antisense primer as previously described (Harada et
al., 1992a, b). The internal standard RNA used in the assays
was synthesised in vitro from modified aromatase cDNA with
0.01 amol of human aromatase RNA containing a 21-base
insertion as an internal standard and amplified by PCR for
26 cycles using a fluorescent dye (FAM) labelled primer. A
FAM-labelled sense primer (5'-TACTACAACCGGGTA-
TATGG-3', the sequence in exon 3) and an antisense primer
(5'-TATTAGAGGTGTCCAGCATG-3', the sequence in
exon 5) were used in the PCR for quantitative analysis of
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Table I Clinicopathological findings and summary of results
Aromatase
mRNA Use
Age Aromatasef (amol ng-1 of
Patient no. (years) Histologya FIGOb MI VI LNd ASe LI total RNA) exon 1
1 51 Well lB < 1/2 (-) (-) (-) + 0.3 Id
2 30 Well lB < 1/2 (-) (-) (-) + + 27.6 lb>ld>lc
3 58 Well lB < 1/2 (-) (-) (-) ND
4 54 Well IC > 1/2 (+) (-) (-) 0.1 Id
5 45 Well lA none (-) (-) (-) + 0.22 Id
6 59 Poor 3C >1/2 (+) (+) (+) + + 3.2 lb>ld
7 69 Mod lB < 1/2 (-) (-) (-) + ND
aWell, well differentiated; mod, moderately differentiated; poor, poorly differentiated; based on Silverberg and Kurman (1992).
bFIGO: surgical staging. C(+) Positive. (-) negative. d(+) Positive, (-) negative. eCytological findings of ascites: (+)positive for
carcinoma cells, (-) negative for carcinoma cells. f-,0.5%; +, 5-25%; + +, more than 25%, positive stroma cells, according to
Watanabe et al. (1995). gUse of exon 1 represents the transcripts ofexon 1 of the human aromatase gene used in cases of human
endometrial carcinoma. MI, myometrial invasion; VI, vascular invasion; LN, lymph nodemetastasis; AS, ascites; LI labelling index;
ND, not detected.
aromatase mRNA. An aliquot (4 Ml) of the fluorescent PCR
products was mixed with 3,l of GENESCAN-1000 ROX
and analysed fluorometrically with a GENE Scanner 362
(Applied Biosystems). The FAM-labelled PCR products
showed two peaks corresponding to PCR products of
aromatase mRNA and the internal standard RNA at
positions of approximately 378 and 399 bp. These two
peaks are designated as AROM mRNA and standard
RNA respectively (Figure la). GENESCAN-1000 ROX,
consisting of DNA size markers labelled with the fluorescent
dye ROX, gave seven peaks of 262, 293, 317, 439, 557, 691
and 695 bp as shown in Figure la. The amount of aromatase
mRNA in the tissue RNA was calculated from the peak
areas of fluorescent products by the internal standard, as
previously described (Harada et al., 1992a, b). The amount
of aromatase mRNA was calculated from the peak areas of
two fluorescent peaks corresponding to aromatase mRNA
and the modified aromatase mRNA (described above) as an
internal standard.
Use of alternative exon I
The use of alternative exons 1 of the aromatase gene was
examined by RT-PCR of the RNA fraction using sense
primers specific for exons la, lb, lc and Id and the
fluorescent dye-labelled antisense primer specific for exon 2,
as described previously (Harada et al., 1993). Harada et al.
(1993) have reported that exons la, lb, lc and Id were used
in aromatase expression of human placenta, skin fibroblasts
and fetal liver, ovary, ovary and prostate, respectively.
Fluorescent PCR products were analysed with a Gene
Scanner 362 (Applied Biosystems). The aromatase mRNAs
transcribed from exons la, lb, lc and ld yielded PCR
products at positions of 402, 327, 368 and 355 bp
respectively. The GENESCAN-1000 ROX was used as
internal size standards (252, 293, 317, 439, 557, 691 and
695 bp), as in quantitative analysis of aromatase mRNA.
Results
The results of aromatase immunoreactivity and mRNA
anlaysis in endometrial carcinoma are summarised in Table I.
Immunohistochemistry
Relatively weak aromatase immunoreactivity was observed in
myometrium, some smooth muscle cells of the vascular wall
and Schwann cells in all the cases examined. Relatively strong
aromatase immunoreactivity was detected in five cases (cases
1, 2, 5, 6 and 7). In these cases, this strong aromatase
immunoreactivity was observed in the stromal cells surround-
ing the carcinomatous glands (Figure 2) or in the nest of the
carcinoma cells. Patterns of aromatase immunolocalisation
were heterogeneous in these cases.
Quantitation of aromatase mRNA
The results are summarised in Table I. Aromatase mRNA was
detected in five of seven endometrial carcinoma specimens
examined. Of the two cases in which aromatase mRNA could
not be detected, one case (case 3) was immunohistochemically
negative for aromatase and the other case (case 7) demon-
strated a (+) aromatase labelling index.
Alternative use ofmultiple exons 1
The results are summarised in Table I. The sizes of PCR
products of exons 1 were 402+3 bp, 327+3 bp, 368 +3 bp
and 355+3 bp for exons la, lb, lc and ld respectively.
Among five carcinoma cases in which aromatase mRNA was
detected, alternative use of multiple exons 1 could be studied
in all five cases. In these five cases, a major transcript using
exon ld was detected in three cases. A major transcript from
exon lb and a minor transcript from exon Id were observed
in one specimen (case 6). The major transcript from exon lb
and minor transcripts from exons Ic and Id were apparent in
one specimen (case 2, Figure lb). Aromatase labelling index
and mRNA amount were higher in these two cases (in which
multiple exons 1, particularly exon lb as a major transcript,
were used in the expression of aromatase gene) than in the
other cases (Table I).
Discussion
Our present study of aromatase expression and its regulation
in human endometrial carcinoma determined by RT-PCR
and immunohistochemistry confirmed previous findings
regarding the presence of aromatase in this tissue
(Watanabe et al., 1995). The gene encoding the P450arom
protein spans approximately 35 kb of DNA and contains
nine exons. Among these nine exons, exon 2 is considered to
contain the translation start site in all tissue in which the
aromatase gene is expressed, but transcription start sites vary
from tissue to tissue (Mahendroo et al., 1991). Aromatase
mRNAs in the ovary and adipose stromal cells of adipose
tissue have been demonstrated to be transcribed, respectively
from 79 and 84 bp upstream of exon 2 identified in human
placenta (Mahendroo et al., 1991; Means et al., 1991),
although the splice junction upstream of the translation start
site in exon 2 is identical in every tissue and the expressed
protein is, therefore, the same regardless of the splicing
patterns. In human endometrium, P450arom expression has
been detected in carcinoma but not in benign counterparts of
this tissue (Watanabe et al., 1995; Bulun et al., 1993, 1994c).
In addition, as has been shown in our study and previous
investigations (Watanabe et al., 1995; Bulun et al., 1994c), the
levels of aromatase expression in patients or in stromal cells
in cancerous tissue from the same patients vary widely, as
does aromatase activity. In addition, the discrepancy betweenAromatase expression in endometrial cancer
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Figure 2 Immunohistochemistry of aromatase in human
endometrioid endometrial carcinoma. Bar=50pjm. Case 2, well-
differentiated carcinoma. C, carcinoma; S, stroma. Arrows
represent immunoreactivity.
immunohistochemistry and RT -PCR analysis observed in
two cases (cases 4 and 7) may be due to degradation of
mRNA in the specimens (case 7) or intratumoral hetero-
geneity of aromatase expression (cases 4 and 7). Recently,
Harada et al. (1993) also demonstrated that a switch from an
adipose-specific exon 1 to another type of exon 1 was
detected in aromatase transcripts in adipose tissues of three
out of five breast cancer specimens. Overexpression of
aromatase has been demonstrated in stromal cells of human
breast cancer, and in situ neoplastic oestrogen production is
also considered to play an important role in the biological
behaviour of human breast malignancies (Sasano et al.,
1994), as in endometrioid endometrial carcinoma. Therefore,
it is very interesting to examine whether or not the abnormal
regulation of aromatase expression as a result of switching of
exons 1 or promoters occurs and whether or not this
alternative splicing is related to overexpression of aromatase
in human endometrial carcinoma.
In our present study, gonadal type or exon Id (Harada et
al 1993) was primarily used in three cases in which
aromatase overexpression was not detected in RT-PCR
and immunohistochemistry. In contrast, the two cases in
which fibroblast type or exon lb was primarily used, with
other exons i as minor transcripts, were associated with
overexpression of aromatase. Placental promoter-specific
P4moarom transcript or exon la was not detected in any of
the cases examined. Bulun et al. (1994c) reported that in one
adenocarcinoma with high aromatase expression, exon Ic and
Id were primarily used, whereas in another mixed muillerian
tumour with much lower expression exons lb, Ic and id were
all used to a similar extent. Therefore, a possible involvement
of alternative splicings, as well as use of multiple exons 1
transcripts in the overexpression of aromatase in human
endometrial carcinoma, remains an unresolved issue because
the number of endometrial carcinoma specimens examined in
our study as well as by Bulun et al. ( 994c) was markedly
limited. It awaits further investigation, including a much
larger study to clarify whether this alteration of exons 1 as
well as use of the multiple exonsi transcripts described
above results in increased aromatase gene expression in the
stromal cells and, subsequently, in overproduction of
oestrogens in situ under the control of new promoters in
human endometrial carcinoma.
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